Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 2/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 6/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15842012 | 1.00 | HTR5A (0.39) | HTR5AKCNA3CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL22627535 | 0.78 | — | — | |
| SCHEMBL6244955 | 0.74 | TAAR1 (0.35) | MEN1KMT2A | |
| SCHEMBL10509524 | 0.70 | TDP1 (0.34) | CYP1A2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL10583695 | 0.70 | TDP1 (0.34) | CYP1A2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL10585757 | 0.70 | TDP1 (0.34) | CYP1A2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4562954 | 0.68 | C3AR1 (0.53) | HTR5AKCNA3CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL4562956 | 0.68 | C3AR1 (0.53) | HTR5AKCNA3CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL3212571 | 0.67 | MMP1 (0.40) | CYP1A2CYP2C19MEN1KMT2AGAA | |
| Octane SCHEMBL28084975 | 0.67 | FKBP5 (0.67) | MMP2MMP9MMP3GPR84MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716369-A | Optimum method for producing pest control agent | 株式会社MMAG | 2022-07-08 | — | — | CN | disclosed |
| CN-109715606-B | Optimum method for producing pest control agent | 株式会社MMAG | 2022-05-10 | — | — | CN | disclosed |
| EP-3318554-B1 | METHOD FOR PRODUCING PEST CONTROL AGENT | MEIJI SEIKA PHARMA CO LTD (JP) | 2021-11-03 | — | — | EP | disclosed |
| EP-3118194-B1 | METHOD FOR PRODUCING 2-ACYLIMINOPYRIDINE DERIVATIVE | MEIJI SEIKA PHARMA CO LTD (JP) | 2020-07-29 | — | — | EP | disclosed |
| US-20190270709-A1 | OPTIMIZED PRODUCTION METHOD FOR PEST CONTROL AGENT | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2019-09-05 | — | — | US | disclosed |
| EP-3514144-A1 | OPTIMIZED PRODUCTION METHOD FOR PEST CONTROL AGENT | Meiji Seika Pharma Co., Ltd. (JP) | 2019-07-24 | — | — | EP | disclosed |
| EP-2749555-B1 | METHOD FOR PRODUCING PEST CONTROLLING AGENT | MEIJI SEIKA PHARMA CO LTD (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-9975851-B2 | Method for producing 2-acyliminopyridine derivative | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9975851-B2 | Method for producing 2-acyliminopyridine derivative | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| EP-3318554-A1 | METHOD FOR PRODUCING PEST CONTROL AGENT | Meiji Seika Pharma Co., Ltd. (JP) | 2018-05-09 | — | — | EP | disclosed |
| US-20140213791-A1 | METHOD FOR PRODUCING PEST CONTROL AGENT | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-07-31 | — | — | US | disclosed |
| US-20140213791-A1 | METHOD FOR PRODUCING PEST CONTROL AGENT | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-07-31 | — | — | US | disclosed |
| EP-2749559-A1 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-2749555-A1 | METHOD FOR PRODUCING PEST CONTROLLING AGENT | Meiji Seika Pharma Co., Ltd. (JP) | 2014-07-02 | — | — | EP | disclosed |
| EP-2749555-A1 | METHOD FOR PRODUCING PEST CONTROLLING AGENT | Meiji Seika Pharma Co., Ltd. (JP) | 2014-07-02 | — | — | EP | disclosed |
| CN-100519491-C | Process for making a linear alpha-olefin oligomer using a heat exchanger | Shell int research co ltd (NL) | 2009-07-29 | — | — | CN | disclosed |
| EP-1546069-B1 | PROCESS FOR MAKING A LINEAR ALPHA-OLEFIN OLIGOMER USING A HEAT EXCHANGER | SHELL INT RESEARCH (NL) | 2009-05-27 | — | — | EP | disclosed |
| CN-1735576-A | Process for making a linear alpha-olefin oligomer using a heat exchanger | SHELL INTRNAT RES B V (NL) | 2006-02-15 | — | — | CN | disclosed |
| EP-1546069-A1 | PROCESS FOR MAKING A LINEAR ALPHA-OLEFIN OLIGOMER USING A HEAT EXCHANGER | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029012-A1 | PROCESS FOR MAKING A LINEAR ALPHA-OLEFIN OLIGOMER USING A HEAT EXCHANGER | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213791-A1 | METHOD FOR PRODUCING PEST CONTROL AGENT | AADAC, ACOT7, APEH | HTR5A 2048/4885KCNA3 1188/4885CYP1A2 106/4885 |
| US-20190270709-A1 | OPTIMIZED PRODUCTION METHOD FOR PEST CONTROL AGENT | NAAA, AKR7A2, DDT | HTR5A 4736/4885KCNA3 2533/4885CYP1A2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.